3-cyclopropylmethyl-9,9-tetramethylene-3,7-diazabicyclo[3,3,1]nonane | 122032-39-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 英文名称: 3-cyclopropylmethyl-9,9-tetramethylene-3,7-diazabicyclo[3,3,1]nonane
• 英文别名: 3-(Cyclopropylmethyl)spiro[3,7-diazabicyclo[3.3.1]nonane-9,1'-cyclopentane]
• CAS: 122032-39-7
• 化学式: C₁₅H₂₆N₂
• 分子量: 234.385
• InChiKey: GJKDHFHCCCCHJH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  对硝基肉桂醛 、 3-cyclopropylmethyl-9,9-tetramethylene-3,7-diazabicyclo[3,3,1]nonane 在 sodium borohydrid 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 7-(4'-nitrocinnamyl)-3-cyclopropylmethyl-9,9-tetramethylene-3,7-diazabicyclo[3,3,1]nonane
  参考文献：
  名称：

  3,7-diazabicyclo(3,3,1)nonane compounds and pharmaceutical compositions

  摘要：

  具有有价值的影响心率药理学特性的3,7-二氮杂双环[3,3,1]壬烷类化合物，对应于公式I： ##STR1## 其中R1是烷基、环烷基烷基或苄基，R2是低碳基，R3是低碳基，或者R2和R3一起形成一个烷基链，而R4代表苯基乙酰基基团，可选地被卤素、低碳氧基、低烷基、羟基或三氟甲基取代，或者是一个肉桂基，可选地被卤素、低碳基、低碳氧基、羟基、硝基或三氟甲基取代。

  公开号：

  US04912113A1

文献信息

• 3,7-Diazabicyclo [3,3,1] nonan-Verbindungen sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
  申请人：Kali-Chemie Pharma GmbH

  公开号：EP0306871B1

  公开（公告）日：1993-12-08
• NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES
  申请人：Advanced Medicine, Inc.

  公开号：EP1086063A1

  公开（公告）日：2001-03-28
• EP1086063A4
  申请人：——

  公开号：EP1086063A4

  公开（公告）日：2001-03-28
• US4912113A
  申请人：——

  公开号：US4912113A

  公开（公告）日：1990-03-27
• [EN] NOVEL POTASSIUM CHANNEL DRUGS AND THEIR USES<br/>[FR] MEDICAMENTS A CANAL POTASSIUM ET LEUR UTILISATION
  申请人：ADVANCED MEDICINE INC

  公开号：WO1999064050A1

  公开（公告）日：1999-12-16

  This invention relates to novel multibinding compounds that bind to potassium (K+) channels and modulate their activity. The compounds of this invention comprise 2-10 K+ channel ligands covalently connected by a linker or linkers, wherein the ligands in their monovalent (i.e., unlinked) state bind to one or more types of K+ channel. The manner of linking the ligands together is such that the multibinding agents thus formed demonstrate an increased biologic and/or therapeutic effect as compared to the same number of unlinked ligands made available for binding to the K+ channel. The invention also relates to methods of using such compounds and to methods of preparing them. The compounds of this invention are particularly useful for treating diseases and conditions of mammals that are mediated by K+ channels. Accordingly, this invention also relates to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and an effective amount of a compound of this invention.